WOBURN, Mass. , July 07, 2021 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin , Ph.D., President and Chief Research & Development Officer of